Advances in(neo)adjuvant therapy for resectable high-risk malig-nant melanoma
10.12092/j.issn.1009-2501.2025.06.015
- VernacularTitle:可切除性高危恶性黑素瘤的(新)辅助治疗研究进展
- Author:
Yongting YANG
1
;
Shuxin HAN
;
Xiaojing KANG
Author Information
1. 新疆大学生命科学与技术学院,新疆生物资源与基因工程重点实验室,乌鲁木齐 830046,新疆;新疆维吾尔自治区人民医院皮肤性病科,乌鲁木齐 830001,新疆;新疆皮肤性病临床医学研究中心,乌鲁木齐 830001,新疆;新疆皮肤病研究重点实验室,乌鲁木齐 830001,新疆
- Publication Type:Journal Article
- Keywords:
melanoma;
radiotherapy;
biochemo-therapy;
immunotherapy;
target therapy
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(6):849-857
- CountryChina
- Language:Chinese
-
Abstract:
Malignant melanoma represents a highly aggressive form of skin cancer.At present,surgical resection remains the primary treatment modality for the majority of patients diagnosed with this condition.However,the five-year disease-free survival rate for high-risk melanoma patients undergoing surgery alone ranges from 40％to 60％.The implementation of preoperative and postoper-ative(neo)adjuvant therapies has been demon-strated to diminish recurrence rates and improve survival outcomes for high-risk surgical patients.Consequently,various(neo)adjuvant treatments for melanoma-including radiotherapy,biochemo-therapy,immunotherapy,and targeted therapy-have been the subject of extensive research in re-cent years.This review aims to summarize the lat-est advancements in(neo)adjuvant therapies for resectable high-risk melanoma patients,with the objective of providing an effective(neo)adjuvant therapy strategy that may improve patient survival and overall prognosis.
